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Abstract
Background Ciclosporin is used as an immunosuppres-
sant in current clinical practice but recent research implies
novel indications for the drug, such as neuro- and cardio-
protection. The intravenous formulation currently on the
market, Sandimmune Injection (Sandimmune), uses
Cremophor EL as emulsifying excipient. Cremophor EL
is known to cause hypersensitivity reactions in some
patients, ranging from skin reactions to potentially fatal
anaphylactic shock.
Objectives The primary objective was to assess if
CicloMulsion, a Cremophor EL-free lipid emulsion of
ciclosporin for intravenous administration, is bioequivalent
to Sandimmune, and the secondary objective was to
compare the tolerability profiles of the two preparations.
Methods This was a single-centre, open-label, subject-
blind, laboratory-blind, single-dose, randomized, two-
treatment, two-period, two-sequence crossover study of the
pharmacokinetics of two formulations of intravenous
ciclosporin. Fifty-two healthy volunteer subjects were
administered 5 mg/kg of each of the two formulations of
ciclosporin as a 4-h intravenous infusion. The last blood
sample was acquired 48 h after the end of the infusion.
Bioequivalence assessments according to current guide-
lines were performed.
Results The geometric mean ratios for CicloMulsion/
Sandimmune (90 % confidence interval [CI]) were 0.90
(0.88, 0.92) for AUC0–last (area under the blood concen-
tration–time curve from time zero to time of last measur-
able concentration) and 0.95 (0.92, 0.97) for Cmax
(maximum blood concentration). For all additional vari-
ables analysed, the 90 % CIs were also within the accepted
bioequivalence range of 0.80–1.25. One anaphylactoid and
one anaphylactic reaction, both classified as serious
adverse events, were reported after treatment with Sand-
immune. No serious adverse events were recorded after
treatment with CicloMulsion.
Conclusion We have assessed the pharmacokinetics and
tolerability of a new Cremophor EL-free lipid emulsion
of ciclosporin, CicloMulsion, compared to Sandim-
mune. The proportion of adverse events was significantly
higher for the Cremophor EL-based product Sandim-
mune. We conclude that CicloMulsion is bioequivalent
to Sandimmune and exhibits fewer adverse reactions.
1 Introduction
Ciclosporin, discovered in 1969 and first registered for
pharmacological use in the early 1980s, is a polypeptide
derived from the fungus species Tolypocladium inflatum. It
binds to cyclophilins, a family of peptidylprolyl isome-
rases, that function as molecular chaperones. In current
clinical practice ciclosporin is utilized as an immunosup-
pressant, reducing the T-lymphocyte function via inhibition
of calcineurin by the ciclosporin–cyclophilin A complex
[1]. Indications include solid organ or bone marrow
transplantation and treatment of autoimmune conditions
such as psoriasis, atopic dermatitis, pyoderma gangreno-
sum, ulcerative colitis, idiopathic nephrotic syndrome and
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inflammatory uveitis [2–8]. Further, ciclosporin binding to
cyclophilin D in the mitochondrial matrix stabilizes
membrane proteins participating in mitochondrial perme-
ability transition, protecting the organelle from negative
effects of oxidative stress and calcium overload. Ciclo-
sporin is thus a promising therapeutic agent in conditions
related to mitochondrial dysfunction such as traumatic
brain injury, myocardial infarction and neurodegenerative
disorders [9–13]. The molecule is highly hydrophobic and
requires a lipophilic solvent for administration. The intra-
venous (IV) form of ciclosporin currently on the market,
Sandimmune Injection (Novartis Pharma Stein AG,
Switzerland) [Sandimmune], is a concentrate for infusion
containing ethanol and polyoxyethylated castor oil,
Cremophor EL (CrEL).
CrEL is not inert [14] and there have been a number of
reports of serious adverse effects after administration of IV
ciclosporin due to reactions to this carrier medium [15–22].
Hypersensitivity reactions to CrEL have also been reported
when used for other IV preparations of drugs such as the
anxiolytic agent diazepam and the anaesthetic drug
Althesin, a combination of alphaxolone and alphadolone
[23–28]. In rodents, neurotoxicity, cardiotoxicity and neph-
rotoxicity due to IV ciclosporin dissolved in CrEL have been
demonstrated [29–32] and, in a canine model, CrEL has
been shown to reduce cardiac output and hepatic blood flow
in a non-dose-dependent fashion [33]. The effects of CrEL
include complement activation, histamine release and severe
hypersensitivity reactions [14, 23, 25, 27].
Ciclosporin in CrEL requires a dilution step prior to
administration. Improper preparation of CrEL-containing
formulations has been reported to cause anaphylactoid
reactions [34, 35]. An additional concern with the use of
ethanol and CrEL is the leaching of plasticizers from
polyvinyl chloride (PVC) bags and infusion sets used in
routine clinical practice. Consequently, preparation and
administration should be done using glass or other non-
PVC infusion sets [36, 37].
Concern about the safety of CrEL as a carrier medium
for IV drugs has been raised on numerous occasions and
several drugs that previously were produced in preparations
with CrEL are now available only with other carrying
media such as lipid emulsions. Known examples are pro-
pofol [23, 38] and diazepam [39]. Others, such as the
chemotherapeutic agent paclitaxel, are available both with
and without CrEL as solvent [40], and the anaesthetic drug
Althesin that contained CrEL is no longer marketed for
use in humans [23, 27, 41].
In this study (ClinicalTrials.gov identifier NCT01692834),
the objective was to assess the pharmacokinetics of a novel
CrEL-and ethanol-free ready-to-use preparation of ciclospo-
rin for IV administration, CicloMulsion (NeuroVive Phar-
maceutical AB, Lund, Sweden), also known as NeuroSTAT,
in relation to the CrEL-containing product currently on the
market (Sandimmune Injection) and to assess whether the
two formulations are bioequivalent. A ready-to-use prepara-
tion without CrEL potentially offers increased patient safety
with fewer adverse events due to improper handling, dilution
or reactions to CrEL.
2 Methods
2.1 Study Design
This was a single-centre, open-label, subject-blind, labo-
ratory-blind, single-dose, randomized, two-treatment,
two-period, two-sequence crossover study of the pharma-
cokinetics of two formulations of IV ciclosporin. The pri-
mary objective was to assess the pharmacokinetics, and the
secondary objective was to compare the tolerability profiles
of the two preparations.
The study protocol, including amendments, subject
information sheets and informed consent documents, were
reviewed by the Ethics Committee of the Faculty of Health
Sciences of the University of the Free State (Reference
number ETOVS 65/09), and by the South African Medi-
cines Control Council (Reference number BE 2009009),
and written approval was acquired. The study was per-
formed in accordance with the declaration of Helsinki and
Guideline for Good Clinical Practice issued by the Inter-
national Conference on Harmonization. It was designed to
comply with the Guidance for Industry—Statistical
Approaches to Establishing Bioequivalence issued by the
United States Department of Health and Human Services,
Food and Drug Administration (FDA) [42], and the Note
for Guidance on the Investigation of Bioavailability and
Bioequivalence by The European Medicines Agency
(EMA) [43].
2.2 Ciclosporin Formulations
The reference formulation of ciclosporin used was Sand-
immune Injection (Novartis Pharma Stein AG, 50 mg/mL
ciclosporin, United States Pharmacopeia, USP) containing
Cremophor EL (each mL of infusion concentrate was
diluted in 20 mL 0.9 % saline solution prior to use). The
test product used was CicloMulsion (NeuroVive Phar-
maceutical AB, Lund, Sweden) 5 mg/mL ready-to-use
Cremophor- and ethanol-free ciclosporin Ph Eur/USP lipid
emulsion. The lipid emulsion carrier is equivalent to the
marketed product Lipovenoes MCT 20 % (Fresenius
Kabi AG, Graz, Austria) and each mL contains 100 mg of
refined soya bean oil, 100 mg of medium-chain triglycer-
ides, 12 mg of egg lecithin, 25 mg of glycerol, water, and
sodium oleate and sodium hydroxide for pH adjustment.
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2.3 Participants
Healthy male and healthy, non-pregnant, non-lactating
female volunteers between 18 and 55 years of age with a
body mass index within the range of 19–33 kg/m2 were
eligible. Further inclusion criteria were body mass
60–100 kg, normal 12-lead electrocardiogram (ECG) and
vital signs, clinically acceptable findings in medical history
and physical examinations, laboratory results within the
reference ranges (unless the deviation was considered
irrelevant for the purpose of the study), willingness to
undergo pre-, interim- and post-study physical examina-
tions and laboratory investigations, ability to comprehend
and willingness to sign statement of informed consent, and
abstinence from tobacco during and 3 months prior to
study. Female participants of childbearing age underwent a
pregnancy test prior to each ciclosporin dosing and, if
positive, were excluded from the study. During the study
period, reliable, non-hormonal methods of contraception
had to be used.
Exclusion criteria included evidence of psychiatric dis-
order, history of or current abuse of drugs (including
alcohol), use of any medication within 2 weeks prior to
first administration of study medication, participation in
another study with an experimental drug with administra-
tion within 12 weeks prior to the current study, major ill-
ness during the last 3 months, donation or loss of blood
exceeding 500 mL during the 8 weeks before the first
administration of the study drug, positive test for hepatitis
B or C or HIV, positive urine drug screen, vaccination of
any kind within 4 weeks of first dose or planning vacci-
nation within 3 months of last dose, close family member
receiving live vaccine during study or within 3 months
post-study, and hypotension or hypertension during
screening period. History of any of the following diseases
was also a criterion for exclusion from the study: any type
of malignancy, immunodeficiency, tendency toward
recurrent infections, known untreated parasitic infection,
allergy to any compound in the reference and test product,
or to egg or soya bean, any bronchospastic diseases, epi-
lepsy, porphyria, psoriasis, atopic dermatitis, hypercho-
lesterolaemia, gout, rheumatoid arthritis or kidney disease.
Care was taken to include both female and male partici-
pants of both Caucasian and non-Caucasian race.
Written informed consent was obtained from all par-
ticipants before study enrollment.
2.4 Sampling Period
Subjects were randomized into two treatment sequences:
the test product followed by the reference product or vice
versa. There was a washout period set to 14–21 days
between the first and second treatment period. Participants
reported to the clinic the night before treatment for labora-
tory testing, including blood samples, pregnancy test and
urine drug screen. The subjects were instructed not to ingest
any citrus fruits and/or apple or pineapple 72 h prior to start
of infusion and, within 24 h, no alcohol or any caffeine-
containing products were permitted. On the clinic day, the
only food served before drug administration was a stan-
dardized breakfast. Through an indwelling IV cannula, the
subjects received either 5 mg/kg CicloMulsion (test) or
5 mg/kg Sandimmune (reference), infused at a constant
rate over 4 h with a syringe pump. The dose recommended
for induction of immunosuppression with Sandimmune in
clinical practice is 3–6 mg/kg/day. The same arm was used
for administration during both treatment periods. All infu-
sion equipment was compatible with both the reference and
the test product. Through an IV cannula in the contra-lateral
arm, a total of 22 blood samples for ciclosporin analysis
were obtained pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5,
4, 4.5, 5, 6, 7, 8, 10, 14, 18, 24, 30, 36 and 48 h after start of
infusion. All samples were collected in vials containing
ethylenediaminetetraacetic acid (EDTA), labeled and stored
at -70 C until analysis. Whole blood ciclosporin-con-
centration was assayed with liquid chromatography-tandem
mass spectrometry. The method was validated according to
current FDA guidelines [44]. The lower limit of quantifi-
cation (LLQ) was 39.39 ng/mL and the mean coefficient of
variation (CV) was 3.5 % for ciclosporin. Complete sets of
calibration standards and quality controls were included
within each run.
Subjects were allowed to leave the clinic 24 h after start
of administration of study medication, provided they
returned for the subsequent collection of blood samples.
Vital signs were monitored during the infusion and recor-
ded 2 h after completion of infusion and after the last blood
sample was drawn. Meals and drinks during clinic days
were standardized. Water was allowed ad libitum before
and after infusion of study medication. Alcohol, caffeine,
citrus fruit, apple and pineapple were not allowed until the
last blood sample was drawn in each treatment period.
2.5 Tolerability Assessment
Each subject was carefully monitored for adverse events
(AEs) during infusion and was questioned on the study day
for any symptoms of such events. AEs were graded as
mild, moderate or severe according to the following
definitions:
Mild: Causing no limitation of usual activities; the
subject may experience slight discomfort.
Moderate: Causing some limitation of usual activities;
the subject may experience annoying discomfort.
Severe: Causing inability to carry out usual activities;
the subject may experience intolerable discomfort or pain.
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The investigator judged each AE with regard to cau-
sality to the administered medical product as ‘‘certain,’’
‘‘probable,’’ ‘‘possible,’’ ‘‘unlikely,’’ ‘‘not related’’ or ‘‘not
assessable’’. Every AE was coded with the Medical
Dictionary for Regulatory Activities (MedDRA) and
reported according to strict criteria. The proportions of
overall AEs and AEs per organ class were compared
between CicloMulsion and Sandimmune by means of
95 % confidence interval (CI) for the difference between
paired proportions and p values from McNemar’s test.
2.6 Pharmacokinetics and Bioequivalence Assessment
Pharmacokinetic variables for ciclosporin were calculated
by use of non-compartmental methods using WinNonlin
Professional version 5.2 (Pharsight Corporation, Mountain
View, CA, USA). Statistical analysis was made using
SAS Software version 9.1 (SAS institute, Cary, NC,
USA). All values below LLQ prior to the first positive
sample were substituted with zero. For the pharmacokinetic
assessment, the terminal values below the LLQ were
ignored.
CicloMulsion was compared to Sandimmune with
respect to a number of pharmacokinetic variables using
analysis of variance (ANOVA) with sequence, subject
within sequence, product and period effects on log-trans-
formed data. The parameters compared were area under the
blood concentration–time curves (AUCs) from time zero to
time of last measurable concentration (AUC0–last), time
zero to infinity (AUC0–?), time 4 h to infinity (AUC4–?),
time zero to time 4 h (AUC0–4) and time 4 h to time of last
measurable concentration (AUC4–last), maximum blood
ciclosporin concentration (Cmax), apparent terminal half-
life (tb), clearance (CL) and mean residence time (MRT).
Cmax, AUC0–?, AUC0–last and AUC4–? were considered
primary variables and the remainder secondary variables.
Point estimates and 90 % CI for the CicloMulsion/
Sandimmune geometric mean ratios of all variables were
calculated. The two products were considered bioequiva-
lent if the 90 % CI for the primary variables fell within the
limits of 0.8 and 1.25.
Based on the FDA and EMA recommended bioequiva-
lence range of 0.80–1.25 for Cmax, AUC0–last and AUC0–?,
an estimated within-subject CV of 35 %, and a test/refer-
ence mean ratio between 0.95 and 1.05, 52 subjects were
needed to achieve a power of 80 % at an alpha level of 0.05
to show bioequivalence [45].
2.7 Modifications in Study Design
The initial study design did not include any premedication,
but, due to an unexpectedly high incidence of serious
adverse events (SAEs) to the reference product, the
remainder of the study was performed with premedica-
tion. An amendment to the study protocol was written
and approved by the ethics committees mentioned above.
For the sake of consistency, premedication was used prior
to infusion of both CicloMulsion and Sandimmune
even though the AEs triggering the initiation of pre-
medication were observed only following Sandimmune
administration. Thirteen subjects completed both treat-
ment periods without premedication. Eighteen subjects
received the test product in the first treatment period
without premedication, and received the reference prod-
uct with premedication in the second treatment period.
The remainder (21 subjects) received premedication
during both treatment periods, and thus with both the test
and reference product.
The premedication consisted of one 50 mg capsule of
diphenhydramine orally 1 h prior to commencement of
infusion of test or reference drug, dexamethasone 10 mg by
slow IV injection, and ranitidine 50 mg IV infusion over
5 min approximately 30 min prior to each dosing of study
drug. The study was put on hold for the protocol amend-
ments to be approved. This caused the washout period for
the 18 subjects who received the test product in the first
treatment period without premedication and the reference
product with premedication in the second treatment period
to be prolonged to more than 6 weeks. None of the
premedications used are known to change the pharmaco-
kinetic properties of ciclosporin or affect the bioanalytical
assay.
3 Results
Sixty-five volunteers were enrolled in the study and ran-
domized to a treatment sequence. Two subjects were
withdrawn before first dosing due to illness, and 11 more
withdrew before completion. Of these 11, three were due to
consent withdrawal, two due to investigator/sponsor deci-
sion (uncertainty of dose received due to problems with
infusion), and six due to AEs. None of these subjects were
included in the bioequivalence analysis. Fifty-two partici-
pants completed the study and were included in the phar-
macokinetic evaluation. The demographics of the subjects
completing the study are presented in Table 1.
Sixty-three participants received at least one dose of
study medication and were monitored for adverse reac-
tions. Due to an unexpectedly high number of serious
adverse reactions to Sandimmune, the study protocol was
changed and premedication as described above was intro-
duced. The statistical analysis of incidence of AEs was
performed solely including the 13 participants who
received both the test and reference drug without pre-
medication, making it less conclusive.
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3.1 Pharmacokinetics and Bioequivalence Assessment
For each time point, arithmetic means with standard deviation
were calculated for the whole blood ciclosporin-concentra-
tions for the test drug CicloMulsion and the reference drug
Sandimmune. A graphical presentation of the ciclosporin
concentrations over time is provided in Fig. 1. In Fig. 2a, b,
concentration–time curves are presented separately for sub-
jects receiving and not receiving concomitant premedication.
The pharmacokinetic parameters are presented in Table 2.
The part of the AUC0–? that was extrapolated was approxi-
mately 5 % for both of the study medications, indicating that a
reliable estimate of the AUC0–? was obtained. No values
below LLQ were present between positive samples.
The statistical analysis of bioequivalence after dosing
with CicloMulsion and Sandimmune is presented in
Table 3. The point estimates of the CicloMulsion/Sand-
immune geometric mean ratios (90 % CI) of the primary
variables Cmax and AUC0–last for ciclosporin were 0.95 (0.92,
0.97) and 0.90 (0.88, 0.92), respectively, and AUC0–? and
AUC4–? for ciclosporin were 0.90 (0.88, 0.92) and 0.87
(0.84, 0.90), respectively. Thus, the 90 % CIs of all primary
variables were within the range acceptable for bioequiva-
lence of 0.80–1.25. The 90 % CI for all secondary variables
also met the criteria for bioequivalence (Table 3).
3.2 Tolerability
Out of 63 subjects, 55 reported one or more AEs. AEs
graded as at least ‘‘possibly’’ related to the study medica-
tion were predominantly reported from the medDRA-coded
organ classes of nervous system disorders and vascular
disorders (Table 4). The nervous system disorders included
headache, burning sensation, paraesthesia, dizziness and
sensory loss. The vascular disorders included events of
hot flushes and orthostatic hypotension. When subjects
received Sandimmune without premedication, 84 %
(16/19) experienced AEs assessed as at least possibly
related to the study medication, compared to 64 % (21/33)
when they received CicloMulsion. With premedication, the
figures were 76 % (31/41) for Sandimmune and 67 % (16/
24) for CicloMulsion. Proportional analysis of AEs was
performed for the subjects treated with both CicloMulsion
and Sandimmune without premedication. There was a
significantly higher proportion of overall AEs (p = 0.003)
and vascular disorders (p = 0.03) when subjects were trea-
ted with Sandimmune. No other proportions were signifi-
cantly different between the two formulations.
Two SAEs were recorded. The first affected a male,
aged 21 years, who in the first treatment period was ran-
domized to receive the reference medication, Sandim-
mune. Directly after the start of infusion he experienced
shortness of breath and a flushing sensation. Infusion was
halted, treatment with 40 % oxygen via Hudson mask was
initiated, and he received promethazine 25 mg and
hydrocortisone 200 mg IV. Due to continuing dyspnoea,
inhalation with nebulized salbutamol was commenced. The
event was considered resolved 37 min after the start of
Table 1 Demographics of subjects included in the pharmacokinetic









Mean (range) 70.4 (60.0–99.8)
BMI (kg/m2)
Mean (range) 23.3 (18.8–28.3)
BMI body mass index
Fig. 1 Arithmetic mean ± SD
of blood concentration of
ciclosporin in participants
administered CicloMulsion or
Sandimmune (n = 52)
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Fig. 2 Arithmetic mean ± SD
of blood concentration of
ciclosporin in participants
administered a CicloMulsion
or b Sandimmune, with or
without premedication
consisting of diphenhydramine
50 mg orally, dexamethasone
10 mg intravenously and
ranitidine 50 mg intravenously
Table 2 Pharmacokinetic parameters of ciclosporin in subjects treated with CicloMulsion or Sandimmune as a single intravenous infusion
over 4 h at a dose of 5 mg/kg
Parameter (unit) CicloMulsion (n = 52) Sandimmune injection (n = 52)
Mean SD CV (%) Mean SD CV (%)
Cmax (ng/mL) 2,972 381 12.8 3,134 386 12.3
AUC0–last (ng  h/mL) 19,412 3,202 16.5 21,679 4,165 19.2
AUC0–? (ng  h/mL) 20,519 3,488 17.0 22,904 4,466 19.5
AUC4–? (ng  h/mL) 11,496 2,569 22.3 13,349 3,626 27.2
AUC0–4 (ng  h/mL) 9,023 1,232 13.7 9,555 1,148 12.0
AUC4–last (ng  h/mL) 10,389 2,240 21.6 12,124 3,256 26.9
CL (mL/h) 17,446 2,543 14.6 15,746 2,860 18.2
MRT (h) 8.8 3.2 36.1 9.1 5.8 63.5
tb (h) 14.6 6.4 43.4 14.7 8.2 55.7
AUC extrapolation (%)a 5.3 2.5 46.6 5.2 4.0 76.7
tmax (h) 3.7 0.4 11.4 3.7 0.4 10.1
AUC area under the blood concentration–time curve, CL clearance, Cmax maximum blood concentration, CV (interindividual) coefficient of
variation, MRT mean residence time, SD standard deviation, tb apparent terminal half-life, tmax time to reach Cmax
a AUC extrapolation is the percentage of AUC0–? extrapolated from AUC0–last
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infusion and oxygen therapy was discontinued. The next
day, he left the clinic but reported feeling tired for another
3 days. The event was diagnosed as an anaphylactoid
reaction.
The second of the two SAEs reported regarded a
42-year-old male who also received the reference drug
Sandimmune in the first treatment period. Eleven minutes
after infusion of the medication commenced he presented
with coughing, facial flushing and dyspnoea. Chest
auscultation revealed wheezing sounds and the peripheral
blood oxygen saturation (SpO2) measured via pulse
oximeter was 95 %. His condition quickly deteriorated, he
became pale and sweaty, and a systolic/diastolic blood
pressure of 75/42 mmHg was recorded. The infusion was
stopped and therapy with 40 % oxygen via Hudson mask
and IV infusion with Ringer lactate commenced. Blood
pressure was not rising and the SpO2 dropped to 91 % after
a couple of minutes; he was treated with 0.5 mg adrenaline
Table 3 Assessment of bioequivalence of whole blood ciclosporin exposure after dosing with a single intravenous dose of CicloMulsion (test)
or Sandimmune Injection (reference)
Parameter (unit) CicloMulsion Sandimmune injection
Geometric meana SD Geometric meana SD Ratiob 90 % CI Within-subject CV (%)
Cmax (ng/mL) 2,949 371 3,111 382 0.95 (0.92, 0.97) 7.7
AUC0–last (ng  h/mL) 19,157 3,162 21,315 3,950 0.90 (0.88, 0.92) 6.7
AUC0–? (ng  h/mL) 20,235 3,431 22,507 4,247 0.90 (0.88, 0.92) 7.5
AUC4–? (ng  h/mL) 11,216 2,562 12,906 3,417 0.87 (0.84, 0.90) 9.9
AUC0–4 (ng  h/mL) 8,943 1,200 9,490 1,113 0.94 (0.92, 0.96) 6.1
AUC4–last (ng  h/mL) 10,150 2,253 11,732 3,061 0.87 (0.84, 0.89) 8.3
CL (mL/h) 17,258 2,608 15,495 2,837 1.11 (1.09, 1.14) 7.5
MRT (h) 8.3 2.8 8.3 3.2 0.99 (0.92, 1.07) 23.4
tb (h) 13.5 5.8 13.3 6.0 1.01 (0.90, 1.14) 37.3
AUC area under the blood concentration–time curve, CI confidence interval, CL clearance, Cmax maximum blood concentration, CV coefficient of
variation, MRT mean residence time, SD standard deviation, tb apparent terminal half-life, tmax time to reach Cmax
a Log-transformed data
b CicloMulsion/Sandimmune injection ratio
Table 4 Summary of all adverse events at least possibly related to study medication
All
subjects






n % n % n % n % n %
Number of subjects exposed 63 19 33 41 24
Total number of subjects with adverse events 54 86 16 84 21 64 31 76 16 67
System organ class
Nervous system disorders 40 63 9 47 16 48 16 39 12 50
Vascular disorders 32 51 8 42 8 24 19 46 2 8
Gastrointestinal disorders 17 27 3 16 7 21 7 17 4 17
Respiratory, thoracic and mediastinal disorders 11 17 1 3 7 17 3 13
Cardiac disorders 6 10 1 3 3 7 3 13
Immune system disorders 6 10 4 21 1 3 1 2 1 4
General disorders and administrative site conditions 5 8 1 3 4 10 1 4
Skin and subcutaneous tissue disorders 4 6 3 7 1 4
Renal and urinary disorders 3 5 3 7 2 8
Reproductive system and breast disorders 3 5 1 5 1 3 1 2
Musculoskeletal and connective tissue disorders 2 3 2 5
Eye disorders 1 2 1 5
Psychiatric disorders 1 2 1 5
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and 25 mg promethazine intramuscularly and 5 mg salbu-
tamol as nebulized inhalation. An infusion of 200 mg
hydrocortisone also commenced. His blood pressure was
normalized 5 min after the first medical intervention;
within an hour all drug treatment could be discontinued.
After 24 h, treatment with IV fluids was halted and the
subject could leave the clinic. He reported feeling fatigued
for another 5 days but could carry out all normal activities.
The event was diagnosed as an anaphylactic reaction. Both
subjects were excluded from the remainder of the study.
Due to the events described above, as well as an allergic
reaction considered moderate and possibly related to
Sandimmune that also caused withdrawal of the subject,
the study was put on hold and an amendment to the study
protocol made with the addition of premedication as
described above.
Three other subjects did not complete the study due to
AEs. These were all moderate and possibly or probably
related to the study medication. Out of these, two par-
ticipants received the test product with premedication and
one the reference product with premedication. No subjects
receiving the test drug CicloMulsion without premedi-
cation experienced AEs causing withdrawal from the
study.
A summary of all AEs at least possibly related to the
study medication is presented in Table 4. There were no
clinically significant or consistent changes in laboratory
values or ECG-findings due to ciclosporin administration.
Vital signs and clinical findings remained essentially
unchanged during the study for all participants except for
the two SAEs described above.
4 Discussion
After a single IV dose of 5 mg/kg, CicloMulsion and
Sandimmune met the conventional criteria for bioequiv-
alence. CicloMulsion was the better tolerated of the two
ciclosporin formulations.
Three patients had to be excluded from the study due to
adverse reactions to Sandimmune; hence the study design
was changed after a decision from local authorities. Due to
the high incidence of SAEs in subjects receiving the CrEL-
based product, premedication was introduced. The calcu-
lated pharmacokinetic parameters between subjects who
did and did not receive premedication were similar, and
bioequivalence could be established with a low within-
subject CV (for most variables under 10 %) including
premedicated and non-premedicated subjects. Thus, the
changes in protocol and the introduction of premedication
did not affect the pharmacokinetic profile of ciclosporin.
For the assessment of tolerability, the change of the study
protocol was not unproblematic. The amendments were
introduced due to an unexpected high incidence of SAEs
attributed to the CrEL-containing reference product, but for
consistency in the pharmacokinetic evaluation, premedi-
cation was also given to subjects receiving the test product.
This made the tolerability assessment less stringent since
only 13 subjects received both drugs without premedica-
tion and could be included in the statistic evaluation. To
draw any definite conclusions about tolerability, random-
ized clinical trials are warranted.
In clinical practice, most CrEL-containing IV drugs
(such as the anti-cancer agent paclitaxel) are administered
with premedication due to the known risk of hypersensi-
tivity reactions to CrEL or, in the case of Sandimmune,
are often given as a part of a combined regimen with
corticosteroids. It is feasible to assume that the actual
incidence of adverse reactions to Sandimmune is
obscured by the protective effect of the corticosteroids.
A number of the reports of CrEL-reactions have been
explained by improper dilution of the Sandimmune Injec-
tion concentrate. CrEL has a greater specific gravity than
water and a high viscosity and, unless properly mixed, will
not be equally partitioned in the infusion bottle. Concentra-
tions of CrEL and ciclosporin up to nine times higher than the
intended dose have been reported during the first 10 min of
infusion when mixed improperly [21, 34, 35]. With a stable,
ready-to-use preparation without the need for dilution, this
would not be an issue.
When Althesin was withdrawn in the late 1980 s
because of serious side effects due to CrEL, some authors
argued that CrEL should not be used as a solvent for future
drugs [46]. Until now, ciclosporin for IV administration has
not been available with any other emulsifying excipient;
this is surprising considering the extensive literature
reporting serious or even fatal CrEL-related reactions
[34, 47]. Even though all pharmacokinetic parameters
evaluated in this study were well within the range of
conventional criteria for bioequivalence, the authors sug-
gest that blood ciclosporin levels should be monitored in
patients where a target blood concentration is required.
Presently, ciclosporin is used mainly after solid organ or
bone marrow transplantations and in the treatment of
autoimmune conditions, but there are other potential indi-
cations for the molecule. Ciclosporin is currently being
investigated as pharmacological therapy in patients
undergoing intervention treatment after myocardial
infarction (the CIRCUS Phase III study, ‘‘Cyclosporine and
Prognosis in Acute Myocardial Infarction [MI] Patients’’,
clinicaltrials.gov identifier NCT01502774). Phase II trials
in traumatic brain injury with ciclosporin have been con-
ducted and further clinical trials are under way using
CicloMulsion / NeuroSTAT [10–13, 48]. For both of
these patient categories, corticosteroids or antihistamines
are not given as a part of standard therapy, possibly
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increasing the risk of allergic reactions to CrEL, and hence,
a better tolerated CrEL-free formulation of ciclosporin
would be advantageous.
There are several previous studies comparing pharma-
cokinetics of orally administered ciclosporin-formulations,
but few for IV administration. In its oral form, ciclosporin
has frequently been found to display a large variation in
bioavailability between individuals [49–53] due to a number
of factors, such as rate of gastric emptying, the rate of biliary,
pancreatic and intestinal secretion, polymorphism in cyto-
chrome P4503A enzymes, and different haplotypes of
p-glycoprotein expressed in the gut wall mucosa. The
intraindividual differences are usually explained by dietary
factors and clinical condition [50–52, 54, 55].
There are examples of IV drugs in which the pharma-
cokinetic profiles have been significantly altered when a
lipid emulsion was introduced as an emulsifier; known
examples are propofol and diazepam [23, 56–58]. Taking
this into account, the estimated within-subject CV was
estimated to be 35 % when designing the study. It turned
out to be under 10 % for all primary variables, supporting
the view that most of the within-subject variation in bio-
availability is due to factors primarily relevant to the orally
administered formulations of ciclosporin. The interindi-
vidual CV % in this study was between 10 and 20 % for
Cmax, AUC0–last and AUC0–?, consistent with previous
reports for IV ciclosporin [49, 59, 60]. The ongoing debate
about the switchability of brand and generic formulations
of orally administered ciclosporin for reasons of variability
should therefore not be extrapolated to IV formulations of
the drug.
5 Conclusion
From the study, we conclude that CicloMulsion, a novel
ciclosporin lipid emulsion developed for IV use, is
bioequivalent to Sandimmune Injection, and that this
ethanol- and Cremophor EL-free, ready-to-use formula-
tion appears to be better tolerated.
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